Equillium Inc
NASDAQ:EQ

  • LAST PRICE
    0.7096
  • TODAY'S CHANGE (%)
    0.0254 (3.7124%)
  • Bid / Lots
    0.6810/ 13
  • Ask / Lots
    0.7218/ 6
  • Open / Previous Close
    0.6637 / 0.6842
  • Day Range
    0.6637
    0.7390
  • 52 Week Range
    0.4789
    3.2500
  • Volume
    127,342

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 13, 2024

      Show headlines and story abstract

    • 4:01PM ET on Wednesday Nov 13, 2024 by MT Newswires
      Companies Mentioned: EQ
      04:01 PM EST, 11/13/2024 (MT Newswires) -- ...

    • 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: EQ
      Accounts receivable 5,009 3,735 Prepaid expenses and other assets 3,098 5,133 Operating lease right-of-use assets 473 796 ----------- ---------- Total assets $ 34,457 $ 50,530 =========== ========== Current liabilities Accounts payable and other current liabilities $ 8,989 $ 11,844 Current portion of deferred revenue 2,068 15,729 ----------- ---------- Total current liabilities 11,057 27,573 Long-term operating lease liabilities 223 384 ----------- ---------- Total liabilities 11,280 27,957 Total stockholders' equity 23,177 22,573 ----------- ---------- Total liabilities and stockholders' equity $ 34,457 $ 50,530 =========== ========== Equillium, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, -------------------------- ---------------------------- 2024 2023 2024 2023 ---------- ---------- ---------- ---------- Revenue $ 12,161 $ 8,870 $ 36,703 $ 26,873 Operating expenses: Research and development 9,562 8,974 30,113 27,855 General and administrative 3,278 3,519 10,161 10,340 ---------- ---------- ---------- ---------- Total operating expenses 12,840 12,493 40,274 38,195 ---------- ---------- ---------- ---------- Loss from operations (679) (3,623) (3,571) (11,322) Total other income, net 672 409 1,298 893 ---------- ---------- ---------- ---------- Loss before income taxes (7) (3,214) (2,273) (10,429) Income tax expense - 496 - 564 ---------- ---------- ---------- ---------- Net loss $ (7) $ (3,710) $ (2,273) $ (10,993) ========== ========== ========== ========== Net loss per share, basic and diluted $ (0.00) $ (0.11) $ (0.06) $ (0.32) ========== ========== ========== ========== Weighted-average number of common shares outstanding, basic and diluted 35,424,388 34,878,700 35,324,092 34,582,574 ========== ========== ========== ==========

    • 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: EQ

    • 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: EQ

      Equillium to Present at the Stifel Healthcare Conference
      LA JOLLA, Calif.--(BUSINESS WIRE)--November 13, 2024--
      Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Stifel Healthcare Conference taking place in New York on November 18 & 19, 2024.

  • Nov 12, 2024